News

Two brothers will travel across the U.S. to raise money for Project ALS to support a project testing a promising drug in people with amyotrophic lateral sclerosis (ALS). Mike Devlin, a 27-year-old ultramarathon runner, will begin his 100-day run in San Francisco on April 15. Mike will run 3,000 miles across America, and…

Israel’s BrainStorm Cell Therapeutics has announced positive top-line Phase 2 data on NurOwn, a customized stem-cell therapy technology to treat amyotrophic lateral sclerosis (ALS). BrainStorm has been developing and commercializing NurOwn in partnership with Ramot, the business engagement unit of Tel Aviv University. NurOwn enables the production of growth factors that…

A novel gene-silencing therapy intended for patients with ALS (amyotrophic lateral sclerosis) is being tested as a treatment for dogs with degenerative myelopathy, a paralytic disease similar to ALS. The study is currently underway at Tufts University. “Giving these pets another one-and-a-half to two years of life would be a major…

Preclinical testing will soon begin in VY-SOD101, a compound seen as a potential treatment for a certain gene mutation found in people with familial amyotrophic lateral sclerosis (ALS).  Its developer,  Voyager Therapeutics, hopes to follow this work, if successful, with clinical trials in patients  in about two years. Patients with ALS typically develop weakness…

Measuring blood levels of the inflammatory marker C-reactive protein (CRP) in patients with amyotrophic lateral sclerosis (ALS) can help physicians track the disease, according to an Italian study of 394 people with ALS. Neuraltus Pharmaceuticals of San Bruno, Calif., believes this study further supports the idea that ALS may respond to inflammation-modulating…

Genervon Biopharmaceuticals has published the results of a somewhat promising Phase 2a clinical trial investigating the effects of GM604 (or GM6) in patients with amyotrophic lateral sclerosis (ALS). The study, “A Phase 2A randomized, double-blind, placebo-controlled pilot trial of GM604 in patients with Amyotrophic Lateral Sclerosis (ALS Protocol GALS-001)…

Scientists have found a potential protein biomarker in the cerebrospinal fluid of people carrying the most common mutation linked to amyotrophic lateral sclerosis (ALS) — suggesting that this protein may be useful to test the effects of drugs to treat this form of ALS in future clinical trials. The study, “Poly(GP) proteins are…

Occupational exposure to extremely low-frequency magnetic fields (ELF-MFs) could trigger amyotrophic lateral sclerosis (ALS), a Dutch study shows. The study, “Occupational exposure and amyotrophic lateral sclerosis in a prospective cohort,” appeared in the journal Occupational & Environmental Medicine. Given that only 5 to 10 percent of ALS cases are hereditary, scientists…

Researchers have found a link between small amounts of metals in the blood in a group of patients with amyotrophic lateral sclerosis (ALS), and the occurrence of the disease in a geographical area that has a higher rate of ALS. While this occurrence cannot be considered to be the sole cause…

Amyotrophic lateral sclerosis (ALS) patients follow no distinct swallowing pattern, and this may account for the development of swallowing difficulties over time that can lead to life-threatening choking, a study reports. The research, “The Importance Of The Reproducibility Of Oropharyngeal Swallowing In Amyotrophic Lateral Sclerosis: An Electrophysiological Study,” was…